The Novelty of Bupropion As a Dopaminergic Antidepressant for the Treatment of Adult Attention Deficit Hyperactive Disorder

Kanit Tha Deang, Hatta Sidi, Hazli Zakaria, Raja Lope Adam, Srijit Das, Nurul Hazwani Hatta, Muhammad Hizri Hatta, Kok Wei Wee

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Attention deficit hyperactive disorder (ADHD), a hyperactivity disorder prevalent among children may continue as an adulthood attention deficit. To date, treating an individual with an adult ADHD may be an arduous task as it involves numerous challenges, which include a need for high index of suspicion to diagnose this medical condition. Many psychiatric disorders masquerade as ADHD and delay the necessary assessment and proper treatment for this debilitating medical disorder. Adult ADHD is often misdiagnosed (or under diagnosed) due to the fact that this medical condition is being masked by the patients' high level of intellectual achievement. As the ADHD in adult persists, it may end-up with impairment in the personal-social-occupational function in which the management becomes a great challenge. The treatment of ADHD can be optimized by using various drugs targets agents like norepinephrine-dopamine reuptake inhibitor (NDRI), with or without psycho stimulants like methylphenidate, which is marketed as Ritalin. Bupropion, an NDRI has a novel effect on ADHD as the molecule exerts its effects by modulating the reward-pleasure mesolimbic dopaminergic system and at the same time regulates the elevating mood dimension of the noradrenergic neurotransmission. The role of Bupropion in the neural and psychopharmacological perspective treatment of ADHD was deliberated. The present review highlights the novel effects of Bupropion in ADHD treatment, together with the help of other successful bio-psycho-social measures. This may be of immense benefit to the psychiatrists for treating their patients.

Original languageEnglish
Pages (from-to)210-219
Number of pages10
JournalCurrent Drug Targets
Volume20
Issue number2
DOIs
Publication statusPublished - 1 Jan 2019

Fingerprint

Bupropion
Attention Deficit Disorder with Hyperactivity
Dopamine Uptake Inhibitors
Antidepressive Agents
Methylphenidate
Norepinephrine
Therapeutics
Molecules
Psychiatry
Pharmaceutical Preparations
Pleasure
Diagnostic Errors
Reward
Synaptic Transmission

Keywords

  • adult ADHD
  • Bupropion
  • novel antidepressants
  • treatment.

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry

Cite this

The Novelty of Bupropion As a Dopaminergic Antidepressant for the Treatment of Adult Attention Deficit Hyperactive Disorder. / Deang, Kanit Tha; Sidi, Hatta; Zakaria, Hazli; Adam, Raja Lope; Das, Srijit; Hatta, Nurul Hazwani; Hatta, Muhammad Hizri; Wee, Kok Wei.

In: Current Drug Targets, Vol. 20, No. 2, 01.01.2019, p. 210-219.

Research output: Contribution to journalArticle

Deang, Kanit Tha ; Sidi, Hatta ; Zakaria, Hazli ; Adam, Raja Lope ; Das, Srijit ; Hatta, Nurul Hazwani ; Hatta, Muhammad Hizri ; Wee, Kok Wei. / The Novelty of Bupropion As a Dopaminergic Antidepressant for the Treatment of Adult Attention Deficit Hyperactive Disorder. In: Current Drug Targets. 2019 ; Vol. 20, No. 2. pp. 210-219.
@article{e2e9f4643f124e4dbfff64fe686a68f0,
title = "The Novelty of Bupropion As a Dopaminergic Antidepressant for the Treatment of Adult Attention Deficit Hyperactive Disorder",
abstract = "Attention deficit hyperactive disorder (ADHD), a hyperactivity disorder prevalent among children may continue as an adulthood attention deficit. To date, treating an individual with an adult ADHD may be an arduous task as it involves numerous challenges, which include a need for high index of suspicion to diagnose this medical condition. Many psychiatric disorders masquerade as ADHD and delay the necessary assessment and proper treatment for this debilitating medical disorder. Adult ADHD is often misdiagnosed (or under diagnosed) due to the fact that this medical condition is being masked by the patients' high level of intellectual achievement. As the ADHD in adult persists, it may end-up with impairment in the personal-social-occupational function in which the management becomes a great challenge. The treatment of ADHD can be optimized by using various drugs targets agents like norepinephrine-dopamine reuptake inhibitor (NDRI), with or without psycho stimulants like methylphenidate, which is marketed as Ritalin. Bupropion, an NDRI has a novel effect on ADHD as the molecule exerts its effects by modulating the reward-pleasure mesolimbic dopaminergic system and at the same time regulates the elevating mood dimension of the noradrenergic neurotransmission. The role of Bupropion in the neural and psychopharmacological perspective treatment of ADHD was deliberated. The present review highlights the novel effects of Bupropion in ADHD treatment, together with the help of other successful bio-psycho-social measures. This may be of immense benefit to the psychiatrists for treating their patients.",
keywords = "adult ADHD, Bupropion, novel antidepressants, treatment.",
author = "Deang, {Kanit Tha} and Hatta Sidi and Hazli Zakaria and Adam, {Raja Lope} and Srijit Das and Hatta, {Nurul Hazwani} and Hatta, {Muhammad Hizri} and Wee, {Kok Wei}",
year = "2019",
month = "1",
day = "1",
doi = "10.2174/1389450118666170511145628",
language = "English",
volume = "20",
pages = "210--219",
journal = "Current Drug Targets",
issn = "1389-4501",
publisher = "Bentham Science Publishers B.V.",
number = "2",

}

TY - JOUR

T1 - The Novelty of Bupropion As a Dopaminergic Antidepressant for the Treatment of Adult Attention Deficit Hyperactive Disorder

AU - Deang, Kanit Tha

AU - Sidi, Hatta

AU - Zakaria, Hazli

AU - Adam, Raja Lope

AU - Das, Srijit

AU - Hatta, Nurul Hazwani

AU - Hatta, Muhammad Hizri

AU - Wee, Kok Wei

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Attention deficit hyperactive disorder (ADHD), a hyperactivity disorder prevalent among children may continue as an adulthood attention deficit. To date, treating an individual with an adult ADHD may be an arduous task as it involves numerous challenges, which include a need for high index of suspicion to diagnose this medical condition. Many psychiatric disorders masquerade as ADHD and delay the necessary assessment and proper treatment for this debilitating medical disorder. Adult ADHD is often misdiagnosed (or under diagnosed) due to the fact that this medical condition is being masked by the patients' high level of intellectual achievement. As the ADHD in adult persists, it may end-up with impairment in the personal-social-occupational function in which the management becomes a great challenge. The treatment of ADHD can be optimized by using various drugs targets agents like norepinephrine-dopamine reuptake inhibitor (NDRI), with or without psycho stimulants like methylphenidate, which is marketed as Ritalin. Bupropion, an NDRI has a novel effect on ADHD as the molecule exerts its effects by modulating the reward-pleasure mesolimbic dopaminergic system and at the same time regulates the elevating mood dimension of the noradrenergic neurotransmission. The role of Bupropion in the neural and psychopharmacological perspective treatment of ADHD was deliberated. The present review highlights the novel effects of Bupropion in ADHD treatment, together with the help of other successful bio-psycho-social measures. This may be of immense benefit to the psychiatrists for treating their patients.

AB - Attention deficit hyperactive disorder (ADHD), a hyperactivity disorder prevalent among children may continue as an adulthood attention deficit. To date, treating an individual with an adult ADHD may be an arduous task as it involves numerous challenges, which include a need for high index of suspicion to diagnose this medical condition. Many psychiatric disorders masquerade as ADHD and delay the necessary assessment and proper treatment for this debilitating medical disorder. Adult ADHD is often misdiagnosed (or under diagnosed) due to the fact that this medical condition is being masked by the patients' high level of intellectual achievement. As the ADHD in adult persists, it may end-up with impairment in the personal-social-occupational function in which the management becomes a great challenge. The treatment of ADHD can be optimized by using various drugs targets agents like norepinephrine-dopamine reuptake inhibitor (NDRI), with or without psycho stimulants like methylphenidate, which is marketed as Ritalin. Bupropion, an NDRI has a novel effect on ADHD as the molecule exerts its effects by modulating the reward-pleasure mesolimbic dopaminergic system and at the same time regulates the elevating mood dimension of the noradrenergic neurotransmission. The role of Bupropion in the neural and psychopharmacological perspective treatment of ADHD was deliberated. The present review highlights the novel effects of Bupropion in ADHD treatment, together with the help of other successful bio-psycho-social measures. This may be of immense benefit to the psychiatrists for treating their patients.

KW - adult ADHD

KW - Bupropion

KW - novel antidepressants

KW - treatment.

UR - http://www.scopus.com/inward/record.url?scp=85041815672&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041815672&partnerID=8YFLogxK

U2 - 10.2174/1389450118666170511145628

DO - 10.2174/1389450118666170511145628

M3 - Article

VL - 20

SP - 210

EP - 219

JO - Current Drug Targets

JF - Current Drug Targets

SN - 1389-4501

IS - 2

ER -